The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent intriguing investment opportunities for those looking beyond major corporations. With strong financial health and solid fundamentals, these smaller or newer companies can offer potential growth at lower price points.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.99	$190.39M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.348	$60.27M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.08	$355.04M	✅ 3 ⚠️ 2 View Analysis >
CI&T (CINT)	$3.88	$515.44M	✅ 5 ⚠️ 0 View Analysis >
Information Services Group (III)	$3.11	$196.42M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.82	$395.62M	✅ 3 ⚠️ 1 View Analysis >
Village Farms International (VFF)	$2.74	$319.99M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$331.71M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.905	$6.57M	✅ 2 ⚠️ 3 View Analysis >

Let's dive into some prime choices out of the screener.

ProKidney (PROK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States, with a market cap of approximately $567.69 million.

Operations: ProKidney generates revenue from its biotechnology startup segment, totaling $0.89 million.

Market Cap: $567.69M

ProKidney Corp., a clinical-stage biotech firm, remains pre-revenue with sales of just US$0.89 million and a net loss of US$68.99 million for 2025. Despite its unprofitability, the company is debt-free and has ample short-term assets (US$280.7 million) to cover liabilities, suggesting financial resilience in the short term. Recent executive changes include appointing Greg Madison as Chief Commercial Officer to spearhead commercial strategies for rilparencel's potential market entry. While revenue growth is projected at a large rate annually, profitability isn't expected within the next three years, underscoring its speculative nature typical of penny stocks.

ProQR Therapeutics (PRQR)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProQR Therapeutics N.V. is a clinical-stage biotechnology company specializing in the discovery and development of novel therapeutic medicines, with a market cap of approximately $172.79 million.

Operations: The company generates its revenue exclusively from the discovery and development of innovative, RNA-based therapeutics, totaling €16.35 million.

Market Cap: $172.79M

ProQR Therapeutics, a clinical-stage biotech company, reported €15.91 million in revenue for 2025 but remains unprofitable with a net loss of €42.18 million. The firm has reduced its debt to equity ratio significantly over the past five years and holds more cash than total debt, indicating prudent financial management. ProQR's short-term assets (€100.1M) comfortably exceed both its short and long-term liabilities, suggesting solid liquidity management despite ongoing losses. Recent strategic moves include establishing an AI Advisory Board to enhance their RNA editing technology development, reflecting proactive steps toward innovation and potential future growth within the competitive biotech sector.

Rocket Pharmaceuticals (RCKT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company that develops, manufactures, and sells genetic therapies for rare and devastating diseases in the United States with a market cap of approximately $394.12 million.

Operations: Rocket Pharmaceuticals does not report distinct revenue segments.

Market Cap: $394.12M

Rocket Pharmaceuticals, a pre-revenue biotech firm with a market cap of US$394.12 million, recently received FDA accelerated approval for KRESLADI, a gene therapy for severe leukocyte adhesion deficiency-I in pediatric patients. Despite lacking revenue and profitability forecasts within the next three years, Rocket's financial position is bolstered by sufficient cash runway and no debt obligations. The company completed follow-on equity offerings totaling US$65.85 million to support ongoing operations and development efforts. While its management team is relatively new with an average tenure of one year, the experienced board provides stability as Rocket navigates its growth trajectory amidst high volatility and insider selling concerns.

Make It Happen

• Access the full spectrum of 343 US Penny Stocks by clicking on this link.
• Seeking Other Investments? These 24 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.